Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AxogenMEX:AXGN 44 12-1 Month Momentum % is N/A% as of Aug. 23, 2026. GuruFocus rates MEX:AXGN with a GF Score™ of 44/100 and a GF Value™ of MXN1,610.37 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 825 Medical Devices & Instruments companies, Axogen ranks better than 98.55% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-23), Axogen's 12-1 Month Momentum % is N/A%.
The industry rank for Axogen's 12-1 Month Momentum % or its related term are showing as below:
MEX:AXGN's 12-1 Month Momentum % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -18.89 * Ranked among companies with meaningful 12-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axogen (MEX:AXGN) has a 12-1 Month Momentum % of N/A% as of Aug. 23, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Axogen and its competitors. According to the industry distribution chart, Axogen ranks #12 out of 825 companies in the Medical Devices & Instruments industry, placing it in the top 1.5%.
Is Axogen's 12-1 Month Momentum % too high?
Axogen's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Axogen ranks #12 out of 825 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Axogen has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Axogen's 12-1 Month Momentum % compare to ?
According to the Medical Devices & Instruments industry distribution chart, Axogen ranks #12 out of 825 companies for 12-1 Month Momentum %. This places Axogen in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Devices & Instruments company?
A good 12-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Axogen and its competitors. Axogen's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axogen stock overvalued right now?
Based on GuruFocus' analysis, Axogen (MEX:AXGN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,610.37, compared to a current price of MXN800.66 — trading 50.3% below its estimated fair value. The current 12-1 Month Momentum % is N/A%. Axogen's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Axogen (MEX:AXGN), the current 12-1 Month Momentum % is N/A% as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Axogen (MEX:AXGN) Overvalued in 2026?
Based on GuruFocus' analysis, Axogen stock appears to be undervalued.
The current stock price of MXN800.66 is trading 50.3% below its estimated GF Value™ of MXN1,610.37.
GuruFocus considers Axogen to be Significantly Undervalued.
Key valuation signals for MEX:AXGN:
12-1 Month Momentum %: N/A%
GF Value™: MXN1,610.37 vs. price of MXN800.66 (50.3% below fair value)
No single metric tells the full story. See the MEX:AXGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
44GF Score
Get the complete analysis for MEX:AXGN
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AXGN has been successfully added to your 
